Free Trial
NASDAQ:AVXL

Anavex Life Sciences (AVXL) Stock Price, News & Analysis

Anavex Life Sciences logo
$6.84
+0.21 (+3.17%)
(As of 11/1/2024 ET)

About Anavex Life Sciences Stock (NASDAQ:AVXL)

Key Stats

Today's Range
$6.50
$7.07
50-Day Range
$5.01
$6.84
52-Week Range
$3.25
$10.45
Volume
2.00 million shs
Average Volume
1.16 million shs
Market Capitalization
$579.58 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$40.00
Consensus Rating
Strong Buy

Company Overview

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

Anavex Life Sciences Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
70th Percentile Overall Score

AVXL MarketRank™: 

Anavex Life Sciences scored higher than 70% of companies evaluated by MarketBeat, and ranked 370th out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Anavex Life Sciences has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Anavex Life Sciences has only been the subject of 1 research reports in the past 90 days.

  • Read more about Anavex Life Sciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Anavex Life Sciences are expected to decrease in the coming year, from ($0.55) to ($0.80) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Anavex Life Sciences is -13.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Anavex Life Sciences is -13.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Anavex Life Sciences has a P/B Ratio of 3.95. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Anavex Life Sciences' valuation and earnings.
  • Percentage of Shares Shorted

    21.12% of the outstanding shares of Anavex Life Sciences have been sold short.
  • Short Interest Ratio / Days to Cover

    Anavex Life Sciences has a short interest ratio ("days to cover") of 22.7, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Anavex Life Sciences has recently increased by 1.82%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Anavex Life Sciences does not currently pay a dividend.

  • Dividend Growth

    Anavex Life Sciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    21.12% of the outstanding shares of Anavex Life Sciences have been sold short.
  • Short Interest Ratio / Days to Cover

    Anavex Life Sciences has a short interest ratio ("days to cover") of 22.7, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Anavex Life Sciences has recently increased by 1.82%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Anavex Life Sciences has a news sentiment score of 0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.41 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Anavex Life Sciences this week, compared to 4 articles on an average week.
  • Search Interest

    Only 5 people have searched for AVXL on MarketBeat in the last 30 days. This is a decrease of -29% compared to the previous 30 days.
  • MarketBeat Follows

    Only 3 people have added Anavex Life Sciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Anavex Life Sciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    11.00% of the stock of Anavex Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 31.55% of the stock of Anavex Life Sciences is held by institutions.

  • Read more about Anavex Life Sciences' insider trading history.
Receive AVXL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Anavex Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

AVXL Stock News Headlines

Anavex Life Sciences (NASDAQ:AVXL) Stock, Option Chain
Sell NVDA Now?
Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's what that means for your money. Billionaire Wall Street investors are quietly offloading millions of shares. What do they know that you don't? It's arguably the most popular stock in the world. Now, one 50-year Wall Street legend says its day in the sun could finally be coming to an end. Last year, he warned of two stocks that went on to crash 60%.
See More Headlines

AVXL Stock Analysis - Frequently Asked Questions

Anavex Life Sciences' stock was trading at $9.31 on January 1st, 2024. Since then, AVXL stock has decreased by 26.6% and is now trading at $6.8350.
View the best growth stocks for 2024 here
.

Anavex Life Sciences Corp. (NASDAQ:AVXL) released its quarterly earnings results on Tuesday, August, 6th. The biotechnology company reported ($0.14) earnings per share for the quarter, beating analysts' consensus estimates of ($0.15) by $0.01.

Top institutional investors of Anavex Life Sciences include Private Advisor Group LLC (0.06%), Creative Planning (0.05%), Forum Financial Management LP (0.04%) and SG Americas Securities LLC (0.03%). Insiders that own company stock include Athanasios Skarpelos, Christopher U Missling, Steffen Thomas and Peter DO Donhauser.
View institutional ownership trends
.

Shares of AVXL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Anavex Life Sciences investors own include Symbotic (SYM), JPMorgan Nasdaq Equity Premium Income ETF (JEPQ), Mesa Air Group (MESA), Innovative Industrial Properties (IIPR), Voya Infrastructure, Industrials and Materials Fund (IDE), Meta Platforms (META) and NVIDIA (NVDA).

Company Calendar

Last Earnings
8/06/2024
Today
11/02/2024
Next Earnings (Estimated)
11/25/2024
Fiscal Year End
9/30/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:AVXL
Fax
N/A
Employees
40
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$40.00
High Stock Price Target
$40.00
Low Stock Price Target
$40.00
Potential Upside/Downside
+485.2%
Consensus Rating
Strong Buy
Rating Score (0-4)
3.50
Research Coverage
2 Analysts

Profitability

Net Income
$-47,510,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.73 per share

Miscellaneous

Free Float
75,468,000
Market Cap
$579.58 million
Optionable
Optionable
Beta
0.61

Social Links

7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

This page (NASDAQ:AVXL) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners